Mark E Burkard

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4414266/publications.pdf

Version: 2024-02-01

81 papers	4,245 citations	201674 27 h-index	118850 62 g-index
85 all docs	85 docs citations	85 times ranked	5114 citing authors

#	Article	IF	Citations
1	Breast cancer immunotherapy: Current biomarkers and the potential of inÂvitro assays. Current Opinion in Biomedical Engineering, 2022, 21, 100348.	3.4	2
2	Classes of therapeutics to amplify the immune response. Breast Cancer Research and Treatment, 2022, 191, 277-289.	2.5	1
3	Quantifying chromosomal instability from intratumoral karyotype diversity using agent-based modeling and Bayesian inference. ELife, 2022, 11, .	6.0	14
4	Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.. Journal of Clinical Oncology, 2022, 40, 1028-1028.	1.6	9
5	Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer. Clinical Breast Cancer, 2021, 21, 292-301.	2.4	4
6	CHARTS: a web application for characterizing and comparing tumor subpopulations in publicly available single-cell RNA-seq data sets. BMC Bioinformatics, 2021, 22, 83.	2.6	9
7	High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability. BMC Cancer, 2021, 21, 186.	2.6	16
8	Centriole and Golgi microtubule nucleation are dispensable for the migration of human neutrophil-like cells. Molecular Biology of the Cell, 2021, 32, 1545-1556.	2.1	5
9	Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples. JCO Precision Oncology, 2021, 5, 1312-1324.	3.0	15
10	Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. Science Translational Medicine, 2021, 13, eabd4811.	12.4	48
11	Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGASâ€“STING Signaling in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2021, 20, 2553-2567.	4.1	35
12	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptorâ€“Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. Journal of Clinical Oncology, 2021, 39, 3171-3181.	1.6	54
13	Centrosome Amplification in Cancer Disrupts Autophagy and Sensitizes to Autophagy Inhibition. Molecular Cancer Research, 2020, 18, 33-45.	3.4	11
14	Visualization of Sequential Treatments in Metastatic Breast Cancer. JCO Clinical Cancer Informatics, 2020, 3, 1-8.	2.1	57
15	Analysis of the â€œcentrosome-omeâ€•identifies MCPH1 deletion as a cause of centrosome amplification in human cancer. Scientific Reports, 2020, 10, 11921.	3.3	5
16	Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. New England Journal of Medicine, 2020, 383, 825-835.	27.0	454
17	Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. Frontiers in Oncology, 2020, 10, 553.	2.8	74
18	Prior Treatment Time Affects Survival Outcomes in Metastatic Breast Cancer. JCO Clinical Cancer Informatics, 2020, 4, 500-513.	2.1	7

#	Article	IF	Citations
19	Chromosomal instability upregulates interferon in acute myeloid leukemia. Genes Chromosomes and Cancer, 2020, 59, 627-638.	2.8	8
20	A Genetic Toggle for Chemical Control of Individual Plk1 Substrates. Cell Chemical Biology, 2020, 27, 350-362.e8.	5.2	1
21	Centrosome amplification is a frequent event in circulating tumor cells from subjects with metastatic breast cancer. Molecular Oncology, 2020, 14, 1898-1909.	4.6	11
22	Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer. Clinical Breast Cancer, 2020, 20, e433-e438.	2.4	8
23	A randomized trial of immediate versus delayed survivorship care plan receipt on patient satisfaction and knowledge of diagnosis and treatment. Cancer, 2019, 125, 1000-1007.	4.1	6
24	Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation. Clinical Cancer Research, 2019, 25, 5376-5387.	7.0	145
25	A physician-scientist preceptorship in clinical and translational research enhances training and mentorship. BMC Medical Education, 2019, 19, 89.	2.4	12
26	Polo-like kinase 4 maintains centriolar satellite integrity by phosphorylation of centrosomal protein 131 (CEP131). Journal of Biological Chemistry, 2019, 294, 6531-6549.	3.4	18
27	MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers. Molecular Cancer Therapeutics, 2019, 18, 346-355.	4.1	24
28	Plk1 protects kinetochoreâ€“centromere architecture against microtubule pulling forces. EMBO Reports, 2019, 20, e48711.	4.5	18
29	Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Molecular Cancer Research, 2018, 16, 517-527.	3.4	43
30	MACROD2, an Original Cause of CIN?. Cancer Discovery, 2018, 8, 921-923.	9.4	7
31	Shared Knowledge in Precision Cancer Care. Wisconsin Medical Journal, 2018, 117, 178-179.	0.3	0
32	Synchronous Bilateral Breast Cancer in a Patient With Nager Syndrome. Clinical Breast Cancer, 2017, 17, e151-e153.	2.4	7
33	Using cancer genomics to guide clinical decisions. Cancer, 2017, 123, 1288-1291.	4.1	0
34	Tuning Chromosomal Instability to Optimize Tumor Fitness. Cancer Discovery, 2017, 7, 134-136.	9.4	11
35	PP2A-Bâ€² holoenzyme substrate recognition, regulation and role in cytokinesis. Cell Discovery, 2017, 3, 17027.	6.7	68
36	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or IIIPIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 6823-6832.	7.0	66

#	Article	IF	Citations
37	Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Investigational New Drugs, 2017, 35, 87-94.	2.6	9
38	Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. JCO Precision Oncology, 2017, 1, 1-10.	3.0	18
39	Photosensitive lichenoid skin reaction to capecitabine. BMC Cancer, 2017, 17, 866.	2.6	9
40	Accuracy and Thoroughness of Treatment Summaries Provided as Part of Survivorship Care Plans Prepared by Two Cancer Centers. Journal of Oncology Practice, 2017, 13, e486-e495.	2.5	12
41	Prospective study of work limitations in cancer patients (pts) undergoing curative chemotherapy (CT).. Journal of Clinical Oncology, 2017, 35, 18-18.	1.6	1
42	Anillin Phosphorylation Controls Timely Membrane Association and Successful Cytokinesis. PLoS Genetics, 2017, 13, e1006511.	3.5	29
43	Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clinical Cancer Research, 2016, 22, 2659-2667.	7.0	39
44	Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. Clinical Breast Cancer, 2016, 16, 256-261.	2.4	19
45	Decoding Polo-like kinase 1 signaling along the kinetochoreâ€“centromere axis. Nature Chemical Biology, 2016, 12, 411-418.	8.0	40
46	Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer. BMC Cancer, 2016, 16, 47.	2.6	89
47	Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer. Molecular Cancer Therapeutics, 2016, 15, 48-59.	4.1	25
48	The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation. PLoS ONE, 2016, 11, e0150225.	2.5	10
49	Centrosome amplification and prognosis in breast cancer.. Journal of Clinical Oncology, 2015, 33, 11036-11036.	1.6	0
50	Centralspindlin assembly and 2 phosphorylations on MgcRacGAP by Polo-like kinase 1 initiate Ect2 binding in early cytokinesis. Cell Cycle, 2014, 13, 2952-2961.	2.6	19
51	â€œTRIMingâ€•the Patient Population to Increase the Benefit of mTOR Inhibition. Journal of the National Cancer Institute, 2014, 106, .	6.3	2
52	Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles. Science Translational Medicine, 2014, 6, 229ra43.	12.4	298
53	Feasibility of 4 Cycles of Docetaxel and Cyclophosphamide Every 14 Days as an Adjuvant Regimen for Breast Cancer: A Wisconsin Oncology Network Study. Clinical Breast Cancer, 2014, 14, 205-211.	2.4	8
54	Update on Adjuvant Chemotherapy for Early Breast Cancer. Breast Cancer: Basic and Clinical Research, 2014, 8, BCBCR.S9454.	1.1	33

#	Article	IF	Citations
55	Abstract 2638: Novel synergy of radiosensitizer prodrug IPdR with Aurora kinase inhibitors in triple-negative breast cancer. , 2014, , .		0
56	Interphase cytofission maintains genomic integrity of human cells after failed cytokinesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13026-13031.	7.1	24
57	High Mitotic Activity of Polo-like Kinase 1 Is Required for Chromosome Segregation and Genomic Integrity in Human Epithelial Cells. Journal of Biological Chemistry, 2012, 287, 42812-42825.	3.4	46
58	Integrating the <scp>NCI</scp>â€60 Data with â€œOmicsâ€•for Drug Discovery. Drug Development Research, 2012, 73, 420-429.	2.9	3
59	Enabling and Disabling Polo-like Kinase 1 Inhibition through Chemical Genetics. ACS Chemical Biology, 2012, 7, 978-981.	3.4	31
60	The Final Link: Tapping the Power of Chemical Genetics to Connect the Molecular and Biologic Functions of Mitotic Protein Kinases. Molecules, 2012, 17, 12172-12186.	3.8	3
61	Aromatase inhibitors and calcium absorption in early stage breast cancer. Breast Cancer Research and Treatment, 2012, 134, 245-251.	2.5	3
62	Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. Breast Cancer Research and Treatment, 2012, 131, 713-721.	2.5	15
63	Abstract 2986: Partial inhibition of Plk1 is cytotoxic despite normal spindle structure. , 2011, , .		0
64	Validating cancer drug targets through chemical genetics. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 251-257.	7.4	6
65	In the interest of full disclosure. Lancet Oncology, The, 2010, 11, 314-315.	10.7	0
66	Plk1 Self-Organization and Priming Phosphorylation of HsCYK-4 at the Spindle Midzone Regulate the Onset of Division in Human Cells. PLoS Biology, 2009, 7, e1000111.	5.6	170
67	Polo Kinase and Cytokinesis Initiation in Mammalian Cells: Harnessing the Awesome Power of Chemical Genetics. Cell Cycle, 2007, 6, 1713-1717.	2.6	10
68	Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 4383-4388.	7.1	228
69	Molecular Recognition in Purine-Rich Internal Loops:Â Thermodynamic, Structural, and Dynamic Consequences of Purine for Adenine Substitutions in 5â€˜(rGGCAAGCCU)2â€,â€¡. Biochemistry, 2002, 41, 14978-14987.	2.5	10
70	Sheared AantiÂ·AantiBase Pairs in a Destabilizing 2 Ã— 2 Internal Loop:Â The NMR Structure of 5â€˜(rGGCAAGCCU)2â€,â€¡. Biochemistry, 2002, 41, 14969-14977.	2.5	15
71	Thermodynamics of RNA Internal Loops with a Guanosine-Guanosine Pair Adjacent to Another Noncanonical Pair. Biochemistry, 2001, 40, 2478-2483.	2.5	23
72	NMR Structures of r(GCAGGCGUGC)2and Determinants of Stability for Single Guanosineâ€'Guanosine Base Pairsâ€,â€¡. Biochemistry, 2000, 39, 11748-11762.	2.5	61

#	Article	IF	Citations
73	Predicting oligonucleotide affinity to nucleic acid targets. Rna, 1999, 5, 1458-1469.	3.5	228
74	The energetics of small internal loops in RNA. Biopolymers, 1999, 52, 157-167.	2.4	31
75	Thermodynamics of Single Mismatches in RNA Duplexesâ€. Biochemistry, 1999, 38, 14214-14223.	2.5	166
76	Thermodynamics of unpaired terminal nucleotides on short RNA helixes correlates with stacking at helix termini in larger RNAs. Journal of Molecular Biology, 1999, 290, 967-982.	4.2	79
77	Thermodynamic Parameters for an Expanded Nearest-Neighbor Model for Formation of RNA Duplexes with Watsonâ^'Crick Base Pairsâ€. Biochemistry, 1998, 37, 14719-14735.	2.5	1,055
78	High Oxygen Partial Pressure in Tissue Delivered by Stabilized Microbubbles. Advances in Experimental Medicine and Biology, 1997, 411, 395-401.	1.6	18
79	Behavior of Bubbles of Slowly Permeating Gas Used for Ultrasonic Imaging Contrast. Investigative Radiology, 1995, 30, 315-321.	6.2	44
80	Simulation of exchanges of multiple gases in bubbles in the body. Respiration Physiology, 1994, 95, 131-145.	2.7	39
81	Genomic instability and carcinogenesis. , 0, , 93-112.		0